An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Ceftazidime/tazobactam (Primary) ; Cefepime; Linezolid; Meropenem; Piperacillin/tazobactam; Vancomycin
- Indications Bacterial infections
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2018 Planned End Date changed from 1 May 2020 to 1 May 2019.
- 11 May 2018 Status changed from not yet recruiting to recruiting.
- 11 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.